Loading clinical trials...
Loading clinical trials...
A Phase 1, Double-blinded, Placebo-controlled Study of Single Ascending Doses of NNC4004-0002 in Adults With Asymptomatic Hyperuricemia
Conditions
Interventions
NNC4004-0002
Placebo
Locations
2
United States
PAREXEL Glendale/LA EPCU
Glendale, California, United States
PAREXEL Intl - EPCU-Baltimore
Baltimore, Maryland, United States
Start Date
November 13, 2024
Primary Completion Date
June 1, 2026
Completion Date
June 1, 2026
Last Updated
September 24, 2025
NCT00104325
NCT07118891
NCT01399385
NCT07295717
NCT03807401
NCT07271693
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions